FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that the Company will release financial results for the second quarter of 2022 on Monday, August 8, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
Monday, August 8, 2022, 8:00 AM EDT
Domestic: 877-407-3088
International: 201-389-0927
Conference ID: 13731437
Webcast: PDS Biotech Earnings Webcast
After the live webcast, the event will be archived on PDS Biotech’s website for six months.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technology platforms. We believe our Versamune® based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company continues to advance its pipeline of preclinical and clinical candidates to address a wide range of cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.
Our Infectimune™ based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses including long-lasting memory T cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology Corporation.
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital
Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…
PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…
IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…
CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…
The Life Sciences BPO Market is expanding rapidly, driven by rising R&D costs, increasing regulatory…
Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…